CLEVELAND, Oct. 22, 2018 /PRNewswire/ -- ViewRay, Inc.
(Nasdaq: VRAY) today announced highlights from its investor &
analyst meeting during the annual meeting of the American Society
for Radiation Oncology (ASTRO) in San Antonio, TX. The meeting
featured presentations highlighting clinical experiences with the
MRIdian System from leading radiation oncologists at the Moffitt
Cancer Center and David Geffen School of Medicine at UCLA.
A presentation by Louis B.
Harrison, M.D., FASTRO, Chair and Senior Member, Department
of Radiation Oncology at Moffitt Cancer Center, highlighted the
opportunity for MRI-guided radiotherapy in the treatment of cancer
and its potential contribution to personalizing radiation therapy
including emerging areas of interest such as optimization of
treatment through an adaptive therapy loop and diffusion weighted
imaging to predict tumor response.
"With MRI-guidance and the ability to adjust dosing during
treatment, physicians now have the unmatched ability to personalize
and adapt radiotherapy to deliver the highest biologically
effective dose to patients while sparing healthy tissue and
critical organs," said Dr. Harrison. "We believe that such an
approach has significant potential to improve patient outcomes,
especially in cancer than has been historically difficult to
treat."
A second presentation given by Michael
L. Steinberg, M.D., Professor and Chair, Department of
Radiation Oncology at the David Geffen School of Medicine at
UCLA, focused on the significantly
improved visualization that is possible with MRI-guidance compared
to cone-beam CT and the ability to observe and manage motion in
real-time when treating tumors in challenging areas such as the
prostate and lung. He highlighted the value of adaptive therapy
done in real-time, which takes into account daily anatomical
changes and allows for both plan adaptation and re-optimization,
versus off-line, which relies on images that are days to weeks old
and thus assumes the anatomical position of both the tumor and
surrounding organs are exactly the same. He stressed the importance
of adaptive therapy in managing movement and deformation of the
tumor and nearby organs at risk, allowing for further dose
escalation.
Dr. Steinberg also discussed the comparable overall cost of
MRI-guided radiotherapy in comparison to CT-guided radiotherapy,
citing the potential for further savings with MRI-guided
radiotherapy through fraction reduction enabled by its increased
precision and the potential to eliminate CT simulation by using MR
simulation only. He also highlighted opportunities for improvements
in value-based metrics with MRI-guided radiotherapy such as
improved outcomes and lower associated healthcare costs, plus
shortened treatment durations and the avoidance of invasive
fiducial placement procedures for patients.
"The integration of MRI with adaptive
radiotherapy represents the next generation in radiation
oncology and a potential new standard of care for treating cancer,"
said Dr. Steinberg. "The patient, clinical and economic benefits
associated with MRI-guided radiotherapy make it highly attractive
to a multitude of stakeholders."
An audio webcast of the meeting is available on the investor
relations section of ViewRay's website at www.viewray.com. A replay
of the webcast will be available for 7 days after the date of the
presentation.
About ViewRay
ViewRay®, Inc. (Nasdaq: VRAY), designs,
manufactures and markets the MRIdian® radiation therapy
system. MRIdian is built upon a proprietary high-definition MR
imaging system designed from the ground up to address the unique
challenges and clinical workflow for advanced radiation oncology
helping to transform radiation therapy, resulting in improved
treatment outcomes that benefit both patients and health care
systems around the world. Unlike MR systems used in diagnostic
radiology, MRIdian's high-definition MR was purposely built to
deliver high-precision radiation without unnecessary beam
distortion, and consequently, help to mitigate skin toxicity and
other safety concerns that may otherwise arise when high magnetic
fields interact with radiation beams. ViewRay and MRIdian are
registered trademarks of ViewRay, Inc.
Intended Use: The MRIdian Linac System, with magnetic
resonance imaging capabilities, is intended to provide stereotactic
radiosurgery and precision radiotherapy for lesions, tumors, and
conditions anywhere in the body where radiation treatment is
indicated.
Forward Looking Statements:
This press release
contains forward-looking statements. Statements in this press
release that are not purely historical are forward-looking
statements. These forward-looking statements are made as of the
date of this press release, and ViewRay assumes no obligation to
update the forward-looking statements, or to update the reasons why
actual results could differ from those projected in the
forward-looking statements, except as required by law. Investors
should consult all of the information set forth herein and should
also refer to the risk factor disclosure set forth in the reports
and other documents ViewRay files with the SEC available at
www.sec.gov, including the risk factors disclosed in ViewRay's
Quarterly Report on Form 10-Q for the quarter ended June 30, 2018.
View original content to download
multimedia:http://www.prnewswire.com/news-releases/real-time-adaptive-radiotherapy-capabilities-of-viewrays-mridian-highlighted-at-investor--analyst-meeting-at-astro-2018-300735103.html
SOURCE ViewRay, Inc.